- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 studyRoche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head trial. Full data haven't yet emerged, but if the drug's survival benefit…Endpoints · 24d ago↗ source
- Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist→ Michel Detheux has succeeded Rita Balice-Gordon as CEO of Danish neuro biotech Muna Therapeutics, which is partnering with GSK on Alzheimer’s treatments. Balice-Gordon will slide over to ...Endpoints · 24d ago↗ source
- BrightGene looks to the West as obesity shot nears China approvalArmed with impressive Phase 3 data, BrightGene is taking its obesity shot to Chinese regulators. It expects trial data in the West to be even stronger, but its search for a partner for ex-China ter…